Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
SUMMARY BET bromodomain inhibitors (BBDI) are candidate therapeutic agents in triple-negative breast cancer (TNBC) and other cancer types, but inherent and acquired resistance to BBDIs limit their potential clinical use. Using CRISPR and small molecule inhibitor screens combined with comprehensive molecular profiling of BBDI response and resistance, we identified synthetic lethal interactions with BBDIs and genes that when deleted confer resistance. We observed synergy with regulators of cell cycle progression, YAP, AXL, and SRC signaling, and chemotherapeutic agents. We also uncovered functional similarities and differences among BRD2, BRD4, and BRD7; while deletion of BRD2 and BRD4 enhances sensitivity to BBDIs, BRD7 loss leads to gain of TEAD/YAP chromatin binding and luminal features associated with BBDI resistance. Single cell RNA-seq and ATAC-seq and cellular barcoding analysis of BBDI responses in sensitive and resistant cell lines highlight significant heterogeneity among samples and demonstrate that BBDI resistance can be either pre-existing or acquired.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
deepTools2: a next generation web server for deep-sequencing data analysis
Ramírez, F., Ryan, D. P., Grüning, B., Bhardwaj, V., Kilpert, F., Richter, A. S., Heyne, S., Dündar, F., & Manke, T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw257 · Cited by 8,096
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 2×
“Directly acting BBD inhibitors (BBDIs), including JQ1 (Filippakopoulos et al., 2010), utilize acetyl-lysine-competitive binding to displace BBD proteins from chromatin, resulting in selective transcriptional responses and anti-proliferative efficacy (Delmore et al.”
BackgroundSelf-citationMaster Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Super-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662 · cited 1×
“The selectivity of BBD inhibition arises from localization of BBDs to super-enhancers (SEs) that regulate cell-specifying and oncogenic transcriptional programs (Chapuy et al., 2013; Hnisz et al., 2013; Lovén et al., 2013; Whyte et al., 2013), producing anti-tumor effects in preclinical models and in clinical trials (…”
BackgroundZehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1×
“Somatic mutations of ARID1A, CTCF, SMARCA4, and PBRM1 are detected at low (1%–5%) frequencies in treatment-naive breast cancers, whereas ARID1Amutations are more common in treatment-resistant distant metastases (Zehir et al., 2017) and in metaplastic breast cancer (Ng et al.”
BackgroundSelective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961 · cited 1×
“The selectivity of BBD inhibition arises from localization of BBDs to super-enhancers (SEs) that regulate cell-specifying and oncogenic transcriptional programs (Chapuy et al., 2013; Hnisz et al., 2013; Lovén et al., 2013; Whyte et al., 2013), producing anti-tumor effects in preclinical models and in clinical trials (…”
BackgroundSelf-citationLi, W., Xu, H., Xiao, T., Cong, L., Love, M. I., Zhang, F., Irizarry, R. A., Liu, J. S., Brown, M., & Liu, X. S. (2014) · Genome Biology · doi:10.1186/s13059-014-0554-4 · Cited by 2,684
Self-citationAn improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues
Corces, M. R., Trevino, A. E., Hamilton, E. G., Greenside, P. G., Sinnott-Armstrong, N. A., Vesuna, S., Satpathy, A. T., Rubin, A. J., Montine, K. S., Wu, B., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4396 · Cited by 2,496
Single-cell chromatin accessibility reveals principles of regulatory variation
Buenrostro, J. D., Wu, B., Litzenburger, U. M., Ruff, D., Gonzales, M. L., Snyder, M. P., Chang, H. Y., & Greenleaf, W. J. (2015) · Nature · doi:10.1038/nature14590 · Cited by 2,308
Du, P., Zhang, X., Huang, C.-C., Jafari, N., Kibbe, W. A., Hou, L., & Lin, S. M. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-587 · Cited by 2,136
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760 · cited 1×
“…Molecular Cell 78, 1096–1113, June 18, 2020 selective small-molecule degrader, dBET6, with improved cellular permeability and improved efficacy (Winter et al., 2015, 2017). dBET6 is a bifunctional molecule consisting of JQ1 appended to phthalimide conjugates via a longer linker compared with…”
BackgroundSelf-citationGarrido-Castro, A. C., Lin, N. U., & Polyak, K. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1177 · Cited by 1,451
Pooling across cells to normalize single-cell RNA sequencing data with many zero counts
L. Lun, A. T., Bach, K., & Marioni, J. C. (2016) · Genome Biology · doi:10.1186/s13059-016-0947-7 · Cited by 1,108
Chapuy, B., McKeown, M. R., Lin, C. Y., Monti, S., Roemer, M. G. M., Qi, J., Rahl, P. B., Sun, H. H., Yeda, K. T., Doench, J. G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.11.003 · Cited by 735 · cited 1×
“The selectivity of BBD inhibition arises from localization of BBDs to super-enhancers (SEs) that regulate cell-specifying and oncogenic transcriptional programs (Chapuy et al., 2013; Hnisz et al., 2013; Lovén et al., 2013; Whyte et al., 2013), producing anti-tumor effects in preclinical models and in clinical trials (…”
BackgroundSelf-citationResponse and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Shu, S., Lin, C. Y., He, H. H., Witwicki, R. M., Tabassum, D. P., Roberts, J. M., Janiszewska, M., Jin Huh, S., Liang, Y., Ryan, J., et al. (2016) · Nature · doi:10.1038/nature16508 · Cited by 632 · cited 14×
“We also calculated luminal-basal-mesenchymal signature scores of wild-type (WT) and BRD7 KO cells because our prior data indicated that BBDI resistance is associated with gain of luminal features (Shu et al., 2016).”
BackgroundMethodResultInfluentialSelf-citationStudying clonal dynamics in response to cancer therapy using high-complexity barcoding
Bhang, H.-E. C., Ruddy, D. A., Krishnamurthy Radhakrishna, V., Caushi, J. X., Zhao, R., Hims, M. M., Singh, A. P., Kao, I., Rakiec, D., Shaw, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3841 · Cited by 507
Self-citationWinter, G. E., Mayer, A., Buckley, D. L., Erb, M. A., Roderick, J. E., Vittori, S., Reyes, J. M., di Iulio, J., Souza, A., Ott, C. J., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.06.004 · Cited by 465
Self-citationEndogenous Purification Reveals GREB1 as a Key Estrogen Receptor Regulatory Factor
Mohammed, H., D’Santos, C., Serandour, A. A., Ali, H. R., Brown, G. D., Atkins, A., Rueda, O. M., Holmes, K. A., Theodorou, V., Robinson, J. L. L., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.01.010 · Cited by 400 · cited 1×
“To characterize BRD4-associated chromatin complexes, we performed rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) and quantitative multiplexed RIME (qPLEX-RIME) (Mohammed et al., 2013; Papachristou et al., 2018) in parental and BBDI-resistant cells in the presence and absence of JQ1.”
MethodSelf-citationHinohara, K., Wu, H.-J., Vigneau, S., McDonald, T. O., Igarashi, K. J., Yamamoto, K. N., Madsen, T., Fassl, A., Egri, S. B., Papanastasiou, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.014 · Cited by 255
Self-citationBET Bromodomain Proteins as Cancer Therapeutic Targets
Shu, S., & Polyak, K. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030908 · Cited by 72
Self-citation
Cited by
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
Wang, S.-W., Gao, C., Zheng, Y.-M., Yi, L., Lu, J.-C., Huang, X.-Y., Cai, J.-B., Zhang, P.-F., Cui, Y.-H., & Ke, A.-W. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01518-8 · Cited by 478
Achieving clinical success with BET inhibitors as anti-cancer agents
Shorstova, T., Foulkes, W. D., & Witcher, M. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01321-0 · Cited by 347
Feng, L., Wang, G., Chen, Y., He, G., Liu, B., Liu, J., Chiang, C., & Ouyang, L. (2022) · Medicinal Research Reviews · doi:10.1002/med.21859 · Cited by 65
“Undoubtedly, synthetic lethal interaction is also a promising new strategy for cancer treatment.(92) Synthetic lethality means that a defect in one of the two genes or proteins in a cell or organism has little effect, but combined defects in both genes/proteins can cause significant impairment.”
Background
Metadata
- Authors
- Shu, S., Wu, H.-J., Ge, J. Y., Zeid, R., Harris, I. S., Jovanović, B., Murphy, K., Wang, B., Qiu, X., Endress, J. E., Reyes, J., Lim, K., Font-Tello, A., Syamala, S., Xiao, T., Reddy Chilamakuri, C. S., Papachristou, E. K., D’Santos, C., Anand, J., Hinohara, K., Li, W., McDonald, T. O., Luoma, A., Modiste, R. J., Nguyen, Q.-D., Michel, B., Cejas, P., Kadoch, C., Jaffe, J. D., Wucherpfennig, K. W., Qi, J., Liu, X. S., Long, H., Brown, M., Carroll, J. S., Brugge, J. S., Bradner, J., Michor, F., & Polyak, K.
- Venue
- Molecular Cell
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 78
- Issue
- 6
- Pages
- 1096-1113.e8
- ISSN
- 1097-2765 (ISSN-L)
- OpenAlex
- W3025750971
- Cited by
- 202
- References
- 29
- FWCI
- 8.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.